Freedom Global analysts maintain a moderately positive outlook on the US biotechnology sector, believing the industry could outperform the market in summer 2026 thanks to a busy calendar of clinical events, conferences, and rising M&A activity.
According to experts, M&A deal volume in biotech reached nearly $49 billion in Q1. Additional support could come from clinical trial results and decisions by the US Food and Drug Administration (FDA), which traditionally act as strong catalysts for biotech stocks.
Among the most interesting investment ideas, analysts highlighted Viridian Therapeutics (VRDN), awaiting an FDA decision on a drug for thyroid eye disease, with a 97% upside potential.
CG Oncology (CGON), preparing to present Phase III oncology trial results and Delix Therapeutics (DFTX), expecting Phase III data for a depression treatment drug, with 48% and 68% upside potentials, respectively, were listed as well.
Freedom Global also named Evommune (EVMN) as a high‑risk but potentially high‑return idea. The company is due to publish Phase II trial results for a chronic urticaria treatment. The target return for the stock is 124%.
At the same time, analysts warned of sector risks, including high US bond yields, pricing pressure on drugs, and a stricter FDA approach to new drug approvals. According to experts, Fed monetary policy and regulatory decisions will remain key factors for biotech companies in coming quarters.
Not an individual investment recommendation.